Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GUAIFENESIN vs FLOWTUSS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Relief of productive cough associated with respiratory tract infections and common cold,Off-label: use as a muscle relaxant (unproven)
Relief of productive cough associated with respiratory tract infections,Chronic obstructive pulmonary disease (COPD) exacerbations,Cystic fibrosis (off-label)
Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
Terminal elimination half-life: 3-5 hours; clinical context: requires dosing every 4-6 hours for sustained mucolytic effect
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (Cr Cl 30–50 m L/min).
Primarily hepatic via oxidation and demethylation; major metabolite is beta-(2-methoxyphenoxy)lactic acid. CYP450 enzymes not significantly involved.
Hepatic metabolism via oxidation and demethylation; primarily excreted renally as metabolites.
Renal: ~95% (primarily as unchanged drug and glucuronide conjugate); biliary/fecal: minimal (<5%)
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
~50% (bound to albumin)
85–90% bound to albumin and alpha-1-acid glycoprotein.
~1 L/kg; clinical meaning: extensive distribution into extravascular tissues, including respiratory secretions
1.5–2.0 L/kg; indicates extensive tissue distribution (e.g., lungs, liver).
Oral: 80-85% (first-pass metabolism minimal)
Oral: 75–85% (first-pass metabolism accounts for 15–25% loss).
No specific guidelines; use caution in severe impairment due to potential accumulation of metabolites.
e GFR 30-60 m L/min: 5 mg every 6 hours; e GFR <30 m L/min: 5 mg every 8 hours.
No adjustment required for mild to moderate impairment; insufficient data for severe impairment.
Child-Pugh Class B: 5 mg every 6 hours; Child-Pugh Class C: 2.5 mg every 8 hours.
Children 2-5 years: 50-100 mg every 4 hours, max 600 mg/day; 6-11 years: 100-200 mg every 4 hours, max 1200 mg/day; ≥12 years: same as adult.
Children 2-6 years: 2.5 mg orally every 6 hours; 6-12 years: 5 mg orally every 6 hours; >12 years: same as adult.
No specific adjustment; use lowest effective dose due to increased sensitivity and risk of adverse effects.
Initial dose 5 mg every 6 hours; increase cautiously due to increased risk of dizziness and sedation.
None
None.
Use with caution in patients with persistent or chronic cough (e.g., smoking, asthma, COPD); if cough persists >7 days or recurs, or with fever/rash/headache, discontinue and evaluate.
Avoid use with persistent or chronic cough (e.g., smoking, asthma, COPD) unless directed by a physician. Use caution in patients with renal impairment.
Hypersensitivity to guaifenesin or any component of the formulation.
Hypersensitivity to guaifenesin or any component; concurrent use with other expectorants.
No significant food interactions. Alcohol may exacerbate CNS depressant effects.
No specific food interactions. Alcohol may increase CNS depressant effects (dizziness, sedation).
Insufficient human data; animal studies show no evidence of fetal harm. Generally considered low risk across all trimesters, though use in first trimester should be cautious due to lack of robust data.
FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dextromethorphan is category C; limited human studies show no clear teratogenic risk, but high doses may cause fetal toxicity. Avoid in first trimester; use only if benefit outweighs risk in second and third trimesters.
Excretion into breast milk is likely minimal; M/P ratio not established. AAP considers compatible with breastfeeding; avoid excessive doses.
Guaifenesin and dextromethorphan are excreted in breast milk in low amounts. M/P ratio not established for either. Use with caution; monitor infant for sedation or respiratory depression.
No dosage adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) are not clinically significant for guaifenesin.
No standard dose adjustment recommended during pregnancy. Use lowest effective dose for shortest duration. Consider pharmacokinetic changes in pregnancy (increased clearance of dextromethorphan may require higher doses for efficacy, but safety limits apply).
Guaifenesin is an expectorant that increases respiratory tract fluid to reduce mucus viscosity. Onset of action is about 30 minutes; duration is 4-6 hours. Maximum effect requires adequate hydration. Avoid in persistent cough due to smoking, asthma, or emphysema. Use caution in renal impairment (Cr Cl <30 m L/min). Not recommended for children under 6 years without medical advice.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretion, reducing mucus viscosity. Onset of action is 30-60 minutes. Maximum effect requires adequate hydration (8-10 glasses of water daily). Not recommended for chronic cough due to smoking, asthma, or emphysema. Avoid use in patients with persistent cough lasting >1 week or accompanied by fever, rash, or headache. May cause dizziness; caution when driving.
Drink plenty of water while taking this medication to help loosen mucus.,Do not take for more than 7 days unless directed by a doctor.,Stop use and consult a doctor if cough persists for more than 7 days, is accompanied by fever, rash, or persistent headache.,Avoid alcohol as it may increase dizziness or drowsiness.,Do not crush or chew extended-release tablets; swallow whole.
Drink plenty of water to help loosen mucus.,Do not take more than 6 doses in 24 hours.,Discontinue and consult doctor if cough persists >7 days or if fever, rash, or headache develop.,Avoid alcohol; may increase dizziness.,Do not use for chronic cough from smoking or asthma without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GUAIFENESIN vs FLOWTUSS, answered by our medical review team.
GUAIFENESIN is a Expectorant that works by Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.. FLOWTUSS is a Expectorant that works by FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GUAIFENESIN and FLOWTUSS depend on the specific clinical indication. These are both Expectorant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GUAIFENESIN is: Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.. The standard adult dose of FLOWTUSS is: 10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GUAIFENESIN and FLOWTUSS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GUAIFENESIN is classified as Category C. Insufficient human data; animal studies show no evidence of fetal harm. Generally considered low risk across all trimesters, though use in first trimester should be cautious due to. FLOWTUSS is classified as Category C. FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dex. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.